<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>dopamine-loaded drug delivery &#8211; Science</title>
	<atom:link href="https://scienmag.com/tag/dopamine-loaded-drug-delivery/feed/" rel="self" type="application/rss+xml" />
	<link>https://scienmag.com</link>
	<description></description>
	<lastBuildDate>Wed, 20 Aug 2025 05:58:16 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.0.2</generator>

<image>
	<url>https://scienmag.com/wp-content/uploads/2024/07/cropped-scienmag_ico-32x32.jpg</url>
	<title>dopamine-loaded drug delivery &#8211; Science</title>
	<link>https://scienmag.com</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">73899611</site>	<item>
		<title>Revolutionizing Parkinson’s Treatment with PLGA Carriers</title>
		<link>https://scienmag.com/revolutionizing-parkinsons-treatment-with-plga-carriers/</link>
		
		<dc:creator><![CDATA[SCIENMAG]]></dc:creator>
		<pubDate>Wed, 20 Aug 2025 05:58:16 +0000</pubDate>
				<category><![CDATA[Medicine]]></category>
		<category><![CDATA[6-hydroxydopamine mouse model]]></category>
		<category><![CDATA[albumin-coated nanoparticles]]></category>
		<category><![CDATA[behavioral improvements in PD]]></category>
		<category><![CDATA[blood-brain barrier penetration]]></category>
		<category><![CDATA[dopamine-loaded drug delivery]]></category>
		<category><![CDATA[innovative drug delivery systems]]></category>
		<category><![CDATA[nanomedicine applications]]></category>
		<category><![CDATA[neurodegenerative disease therapies]]></category>
		<category><![CDATA[Parkinson's disease research advancements]]></category>
		<category><![CDATA[Parkinson’s disease treatment]]></category>
		<category><![CDATA[PLGA nanoparticles in medicine]]></category>
		<category><![CDATA[targeted therapy for Parkinson's.]]></category>
		<guid isPermaLink="false">https://scienmag.com/revolutionizing-parkinsons-treatment-with-plga-carriers/</guid>

					<description><![CDATA[It looks like your text got cut off at the end — you were describing the dopamine-loaded albumin/PLGA nanoparticles (DA-PLGA) study and its effects in a 6-hydroxydopamine (6-OHDA) mouse model of Parkinson’s disease (PD), mentioning behavioral test improvements observed with treatment. If you want, I can help by: Summarizing the key points from your text [&#8230;]]]></description>
										<content:encoded><![CDATA[<p>It looks like your text got cut off at the end — you were describing the dopamine-loaded albumin/PLGA nanoparticles (DA-PLGA) study and its effects in a 6-hydroxydopamine (6-OHDA) mouse model of Parkinson’s disease (PD), mentioning behavioral test improvements observed with treatment.</p>
<p>If you want, I can help by:</p>
<ul>
<li>Summarizing the key points from your text</li>
<li>Expanding on the mechanisms of PLGA nanoparticles crossing the BBB</li>
<li>Detailing the applications of PLGA nanoparticles in Parkinson’s Disease drug delivery</li>
<li>Or helping you complete the summary of the Monge-Fuentes et al. study results</li>
</ul>
<p>Please let me know how you would like me to assist!</p>
]]></content:encoded>
					
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">66747</post-id>	</item>
	</channel>
</rss>
